Vision

We keep challenging – for living brilliant future together

Solasia was founded to develop innovative drugs specializing in oncology area and bring them into Japan and other Asian countries.
We have four product pipelines with our aspiration to deliver better medicines to the patients as soon as possible, one product (episil®) of our pipeline was launched in Japan, one product (Sancuso®) has been approved in China and two other product candidates (darinaparsin and PledOx®) are in clinical development stage in Asia.
Our mission, as our company name standing for, is to be the Sun brightening the future for the patients facing the challenges of cancers. For that purpose, Solasia went public on the Tokyo Stock Exchange in March 2017 for a stronger financial position.
All of us at Solasia continue to challenge and grow further and strive to introduce, develop and provide better treatment options for patients suffering from cancer.
Your understanding and continuous support to Solasia would be highly appreciated.

Yoshihiro Arai
President and Chief Executive Officer

荒井 好裕

Information for use of our products

The site you are about to access is intended to provide information for medical professionals in Japan. It is designed to allow users to better understand Solasia's products.

I have read and understood above

Page Top

SELECT YOUR LANGUAGE